Dosing protocol · Healing & Recovery
Thymosin Beta-4 dosing & administration
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
Suggested dose
2 – 5 mg
137 peptides · 10 goals
Goals
Cognitive
Cosmetic
Growth Hormone
Healing & Recovery
Hormone Support
Immune
Metabolic
Mitochondrial
Sexual Health
Sleep & Recovery
Dosing protocol · Healing & Recovery
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
Suggested dose
2 – 5 mg
Dosing
Subcutaneous injection
Subcutaneous injection: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2-5 mg (community injectable practice for 'TB-500')
Documented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route . Not an FDA-approved use.
Topical ophthalmic (eye drops)
Topical ophthalmic (eye drops): Applied onto the skin as a cream, gel, or lotion — it works mainly where you put it.
Bioavailability Local — acts mainly at the skin; little reaches the bloodstream.
Intravenous injection
Intravenous injection: Delivered straight into a vein through a drip (IV), done by a clinician.
Bioavailability Complete (about 100%) — delivered straight into the bloodstream.
Timing
Best time to take
Morning or evening (flexible)
With food?
Not affected by food intake
If stacking
Best administered on different days than other injectable peptides to minimize injection site stress
Adjusting your dose
Increase if
Decrease if
Signs of right dose
Administration
Reconstitution
What you need
Injection
Route
Subcutaneous
Best sites
Storage
Before reconstitution
Keep in original vial at 2-8°C. Protect from light and freezing. Stable for 36+ months when properly stored
After reconstitution
Store at 2-8°C in refrigerator. Do not freeze reconstituted solution
Signs of degradation — discard the vial
Sample daily schedule
Monday morning
2-5 mg injection
Site: Lower abdomen or outer thigh
First dose of the week (loading phase)
Thursday morning
2-5 mg injection
Site: Opposite thigh or upper arm
Second dose of the week (loading phase, then transition to maintenance)
Weekly (maintenance)
2 mg injection
Site: Rotate between abdomen, thighs, and arms
After 4-6 week loading phase, reduce to once weekly for maintenance
Safety
Side effects
Commonly reported: Injection site redness, Injection site swelling
Less common: Temporary mild headache, Mild bruising at injection site, Transient fatigue
Serious side effects
Stop and seek help if
This is general educational information. Always consult with a healthcare provider before starting, stopping, or modifying any peptide therapy. Do not self-diagnose or treat serious medical conditions.
Interaction notes · no rating stored
Published research
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
This study investigated the properties and effects of Thymosin Beta-4, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide
This study investigated the properties and effects of Thymosin Beta-4, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Thymosin beta4 and cardiac repair
This study investigated the properties and effects of Thymosin Beta-4, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock
This study investigated the properties and effects of Thymosin Beta-4, contributing to our understanding of its mechanism of action and potential therapeutic applications.
0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution Promotes Healing in Neurotrophic Keratopathy: a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 (RGN-352) for Treating Acute Myocardial Infarction
Head to head
Studied for
The complete Thymosin Beta-4 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.